Deciphering the Agonist Binding Mechanism to the Adenosine A1 Receptor

Giuseppe Deganutti; Kerry Barkan; Barbara Preti; Michele Leuenberger; Mark Wall; Bruno G Frenguelli; Martin Lochner; Graham Ladds; Christopher A Reynolds

doi:10.1021/acsptsci.0c00195

Deciphering the Agonist Binding Mechanism to the Adenosine A1 Receptor

Giuseppe Deganutti, Kerry Barkan, Barbara Preti, Michele Leuenberger, Mark Wall, Bruno G Frenguelli, Martin Lochner, Graham Ladds, Christopher A Reynolds

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

12 Downloads (Pure)

Abstract

Despite being among the most characterized G protein-coupled receptors (GPCRs), adenosine receptors (ARs) have always been a difficult target in drug design. To date, no agonist other than the natural effector and the diagnostic regadenoson has been approved for human use. Recently, the structure of the adenosine A1 receptor (A1R) was determined in the active, Gi protein complexed state; this has important repercussions for structure-based drug design. Here, we employed supervised molecular dynamics simulations and mutagenesis experiments to extend the structural knowledge of the binding of selective agonists to A1R. Our results identify new residues involved in the association and dissociation pathway, they suggest the binding mode of N6-cyclopentyladenosine (CPA) related ligands, and they highlight the dramatic effect that chemical modifications can have on the overall binding mechanism, paving the way for the rational development of a structure-kinetics relationship of A1R agonists.

Original language	English
Pages (from-to)	314-326
Number of pages	13
Journal	ACS Pharmacology and Translational Science
Volume	4
Issue number	1
Early online date	20 Jan 2021
DOIs	https://doi.org/10.1021/acsptsci.0c00195
Publication status	Published - 12 Feb 2021

Bibliographical note

This document is the Accepted Manuscript version of a Published Work that appeared in final form in ACS Pharmacology and Translational Science, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see https://dx.doi.org/10.1021/acsptsci.0c00195

Funder

Leverhulme Trust (Grant RPG-2017-255, C.A.R. and G.L. to fund K.B. and G.D.)

Keywords

G protein coupled receptors
GPCRs
Adenosine A1 receptor
A1R supervised molecular dynamics
SuMD
mutagenesis experiments
binding
Binding
A R
Mutagenesis experiments
Supervised molecular dynamics

ASJC Scopus subject areas

Pharmacology (medical)
Pharmacology

Access to Document

10.1021/acsptsci.0c00195

Post-PrintAccepted author manuscript, 1.65 MB

Cite this

Deciphering the Agonist Binding Mechanism to the Adenosine A1 Receptor. / Deganutti, Giuseppe; Barkan, Kerry; Preti, Barbara; Leuenberger, Michele; Wall, Mark; Frenguelli, Bruno G; Lochner, Martin; Ladds, Graham; Reynolds, Christopher A.

In: ACS Pharmacology and Translational Science, Vol. 4, No. 1, 12.02.2021, p. 314-326.

Research output: Contribution to journal › Article › peer-review

@article{14e1e65a5c8448ae8ffede7af60f43b8,

title = "Deciphering the Agonist Binding Mechanism to the Adenosine A1 Receptor",

abstract = "Despite being among the most characterized G protein-coupled receptors (GPCRs), adenosine receptors (ARs) have always been a difficult target in drug design. To date, no agonist other than the natural effector and the diagnostic regadenoson has been approved for human use. Recently, the structure of the adenosine A1 receptor (A1R) was determined in the active, Gi protein complexed state; this has important repercussions for structure-based drug design. Here, we employed supervised molecular dynamics simulations and mutagenesis experiments to extend the structural knowledge of the binding of selective agonists to A1R. Our results identify new residues involved in the association and dissociation pathway, they suggest the binding mode of N6-cyclopentyladenosine (CPA) related ligands, and they highlight the dramatic effect that chemical modifications can have on the overall binding mechanism, paving the way for the rational development of a structure-kinetics relationship of A1R agonists.",

keywords = "G protein coupled receptors, GPCRs, Adenosine A1 receptor, A1R supervised molecular dynamics, SuMD, mutagenesis experiments, binding, Binding, A R, Mutagenesis experiments, Supervised molecular dynamics",

author = "Giuseppe Deganutti and Kerry Barkan and Barbara Preti and Michele Leuenberger and Mark Wall and Frenguelli, {Bruno G} and Martin Lochner and Graham Ladds and Reynolds, {Christopher A}",

note = "This document is the Accepted Manuscript version of a Published Work that appeared in final form in ACS Pharmacology and Translational Science, copyright {\textcopyright} American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see https://dx.doi.org/10.1021/acsptsci.0c00195",

year = "2021",

month = feb,

day = "12",

doi = "10.1021/acsptsci.0c00195",

language = "English",

volume = "4",

pages = "314--326",

journal = "ACS Pharmacology and Translational Science",

issn = "2575-9108",

publisher = "American Chemical Society",

number = "1",

}

TY - JOUR

T1 - Deciphering the Agonist Binding Mechanism to the Adenosine A1 Receptor

AU - Deganutti, Giuseppe

AU - Barkan, Kerry

AU - Preti, Barbara

AU - Leuenberger, Michele

AU - Wall, Mark

AU - Frenguelli, Bruno G

AU - Lochner, Martin

AU - Ladds, Graham

AU - Reynolds, Christopher A

N1 - This document is the Accepted Manuscript version of a Published Work that appeared in final form in ACS Pharmacology and Translational Science, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see https://dx.doi.org/10.1021/acsptsci.0c00195

PY - 2021/2/12

Y1 - 2021/2/12

N2 - Despite being among the most characterized G protein-coupled receptors (GPCRs), adenosine receptors (ARs) have always been a difficult target in drug design. To date, no agonist other than the natural effector and the diagnostic regadenoson has been approved for human use. Recently, the structure of the adenosine A1 receptor (A1R) was determined in the active, Gi protein complexed state; this has important repercussions for structure-based drug design. Here, we employed supervised molecular dynamics simulations and mutagenesis experiments to extend the structural knowledge of the binding of selective agonists to A1R. Our results identify new residues involved in the association and dissociation pathway, they suggest the binding mode of N6-cyclopentyladenosine (CPA) related ligands, and they highlight the dramatic effect that chemical modifications can have on the overall binding mechanism, paving the way for the rational development of a structure-kinetics relationship of A1R agonists.

AB - Despite being among the most characterized G protein-coupled receptors (GPCRs), adenosine receptors (ARs) have always been a difficult target in drug design. To date, no agonist other than the natural effector and the diagnostic regadenoson has been approved for human use. Recently, the structure of the adenosine A1 receptor (A1R) was determined in the active, Gi protein complexed state; this has important repercussions for structure-based drug design. Here, we employed supervised molecular dynamics simulations and mutagenesis experiments to extend the structural knowledge of the binding of selective agonists to A1R. Our results identify new residues involved in the association and dissociation pathway, they suggest the binding mode of N6-cyclopentyladenosine (CPA) related ligands, and they highlight the dramatic effect that chemical modifications can have on the overall binding mechanism, paving the way for the rational development of a structure-kinetics relationship of A1R agonists.

KW - G protein coupled receptors

KW - GPCRs

KW - Adenosine A1 receptor

KW - A1R supervised molecular dynamics

KW - SuMD

KW - mutagenesis experiments

KW - binding

KW - Binding

KW - A R

KW - Mutagenesis experiments

KW - Supervised molecular dynamics

UR - http://www.scopus.com/inward/record.url?scp=85100246318&partnerID=8YFLogxK

U2 - 10.1021/acsptsci.0c00195

DO - 10.1021/acsptsci.0c00195

M3 - Article

C2 - 33615181

VL - 4

SP - 314

EP - 326

JO - ACS Pharmacology and Translational Science

JF - ACS Pharmacology and Translational Science

SN - 2575-9108

IS - 1

ER -

Deciphering the Agonist Binding Mechanism to the Adenosine A1 Receptor

Abstract

Bibliographical note

Funder

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this